Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
Introduction The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD). Objectives The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after esketamine use. Methods Descriptive, retrosp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822007623/type/journal_article |
| _version_ | 1797616751373975552 |
|---|---|
| author | D. Hernandez Huerta A. De Santiago Diaz C. Rodriguez Gomez-Carreño M.A. Abril Garcia F. Toledo Romero A. Guerrero Morcillo C.J. Martinez Pastor M. Vega Piñero |
| author_facet | D. Hernandez Huerta A. De Santiago Diaz C. Rodriguez Gomez-Carreño M.A. Abril Garcia F. Toledo Romero A. Guerrero Morcillo C.J. Martinez Pastor M. Vega Piñero |
| author_sort | D. Hernandez Huerta |
| collection | DOAJ |
| description |
Introduction
The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD).
Objectives
The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after esketamine use.
Methods
Descriptive, retrospective and multicenter study carried out in Spain. Patients with TRD who had received esketamine treatment, and for whom there were clinical data of subsequent evolution, were included. The scores on the MADRS and Hamilton scales were changed into scores on the CGI scale according to the studies by Leucht et al. The Student’s t test was performed to assess differences in the CGI.
Results
Eleven patients were included: 72.7% were women and the mean age was 56 (SD: 12.9). The maximum dose of esketamine used was 84mg in 63.7%. The onset of antidepressant action was observed from the 1st dose in 72.6% of the patients. The mean time in treatment was 6.6 months (SD: 2.3) and 90.9% reached remission criteria. After 7.4 months (SD: 3.0) from the end of the treatment, 90.9% remained in remission and without visits to the emergency room or hospitalization for psychiatric reasons. The mean baseline score on the CGI-SI was 5.7 points, at the end of the treatment was 1.2 points and after longitudinal follow-up it was 1. Statistically significant differences were observed (p<0.001) both at the end of the treatment and in the post-esketamine follow-up compared with baseline score.
Conclusions
In our sample, the use of esketamine in TRD shows clinical stability in the medium-term follow-up.
Disclosure
Daniel Hernández has participated in medical meetings and/or received payment for presentations from Otsuka, Lundbeck, Janssen, Angelini, Casen Recordati, and Ferrer.
|
| first_indexed | 2024-03-11T07:44:42Z |
| format | Article |
| id | doaj.art-e5a55c0d65e14c2dacb024435507f68a |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:44:42Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-e5a55c0d65e14c2dacb024435507f68a2023-11-17T05:07:50ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S298S29910.1192/j.eurpsy.2022.762Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depressionD. Hernandez Huerta0A. De Santiago Diaz1C. Rodriguez Gomez-Carreño2M.A. Abril Garcia3F. Toledo Romero4A. Guerrero Morcillo5C.J. Martinez Pastor6M. Vega Piñero7Ramon y Cajal University Hospital, Department Of Psychiatry, Madrid, SpainUniversity Hospital Marqués de Valdecilla, Department Of Psychiatry, Santander, SpainUniversity Hospital of Ciudad Real, Department Of Psychiatry, Ciudad Real, SpainUniversity Hospital Gómez Ulla, Department Of Psychiatry, Madrid, SpainUniversity Hospital Virgen de la Arrixaca, Department Of Psychiatry, Murcia, SpainGeneral Hospital of Villarrobledo, Department Of Psychiatry, Albacete, SpainUniversity Hospital of Elche, Department Of Psychiatry, Elche, SpainUniversity Hospital Ramón y Cajal, Department Of Psychiatry, Madrid, Spain Introduction The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD). Objectives The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after esketamine use. Methods Descriptive, retrospective and multicenter study carried out in Spain. Patients with TRD who had received esketamine treatment, and for whom there were clinical data of subsequent evolution, were included. The scores on the MADRS and Hamilton scales were changed into scores on the CGI scale according to the studies by Leucht et al. The Student’s t test was performed to assess differences in the CGI. Results Eleven patients were included: 72.7% were women and the mean age was 56 (SD: 12.9). The maximum dose of esketamine used was 84mg in 63.7%. The onset of antidepressant action was observed from the 1st dose in 72.6% of the patients. The mean time in treatment was 6.6 months (SD: 2.3) and 90.9% reached remission criteria. After 7.4 months (SD: 3.0) from the end of the treatment, 90.9% remained in remission and without visits to the emergency room or hospitalization for psychiatric reasons. The mean baseline score on the CGI-SI was 5.7 points, at the end of the treatment was 1.2 points and after longitudinal follow-up it was 1. Statistically significant differences were observed (p<0.001) both at the end of the treatment and in the post-esketamine follow-up compared with baseline score. Conclusions In our sample, the use of esketamine in TRD shows clinical stability in the medium-term follow-up. Disclosure Daniel Hernández has participated in medical meetings and/or received payment for presentations from Otsuka, Lundbeck, Janssen, Angelini, Casen Recordati, and Ferrer. https://www.cambridge.org/core/product/identifier/S0924933822007623/type/journal_articleDepressionesketamineTreatment-resistant depression |
| spellingShingle | D. Hernandez Huerta A. De Santiago Diaz C. Rodriguez Gomez-Carreño M.A. Abril Garcia F. Toledo Romero A. Guerrero Morcillo C.J. Martinez Pastor M. Vega Piñero Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression European Psychiatry Depression esketamine Treatment-resistant depression |
| title | Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression |
| title_full | Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression |
| title_fullStr | Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression |
| title_full_unstemmed | Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression |
| title_short | Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression |
| title_sort | clinical stability after compassionate use of intranasal esketamine in treatment resistant depression |
| topic | Depression esketamine Treatment-resistant depression |
| url | https://www.cambridge.org/core/product/identifier/S0924933822007623/type/journal_article |
| work_keys_str_mv | AT dhernandezhuerta clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT adesantiagodiaz clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT crodriguezgomezcarreno clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT maabrilgarcia clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT ftoledoromero clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT aguerreromorcillo clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT cjmartinezpastor clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression AT mvegapinero clinicalstabilityaftercompassionateuseofintranasalesketamineintreatmentresistantdepression |